Corcept Therapeutics (CORT) Accounts Payables (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Accounts Payables data on file, last reported at $33.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 19.18% year-over-year to $33.3 million; the trailing twelve-month figure through Mar 2026 stood at $33.3 million (up 19.18% YoY), and the FY2025 full-year result was $40.4 million, up 163.03% from the prior year.
• Accounts Payables eased to $33.3 million in Q1 2026, from $40.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $40.4 million in Q4 2025 to a low of $8.0 million in Q2 2023.
• A 5-year average of $18.6 million and a median of $16.7 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables dropped 11.61% in 2024 and soared 163.03% in 2025, its largest moves.
• Tracing CORT's Accounts Payables over 5 years: stood at $12.0 million in 2022, then jumped by 45.26% to $17.4 million in 2023, then slipped by 11.61% to $15.4 million in 2024, then surged by 163.03% to $40.4 million in 2025, then dropped by 17.65% to $33.3 million in 2026.
• Business Quant data shows CORT's Accounts Payables at $33.3 million in Q1 2026, $40.4 million in Q4 2025, and $34.4 million in Q3 2025.